Table1 Clinical and pathological data of all patients and propensity score-matched cohorts
Variables | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
Low AST/ALT ratio (n = 139) | High AST/ALT ratio (n = 175) | P valuea | Low AST/ALT ratio (n = 102) | High AST/ALT ratio (n = 102) | P valueb | |
Age, n (%) | 0.007* | 0.597 | ||||
≤ 60 year | 59 (42.4) | 49 (28.0) | 31 (30.4) | 35 (34.3) | ||
> 60 year | 80 (57.6) | 126 (72.0) | 71 (69.6) | 67 (65.7) | ||
Gender, n (%) | 0.133 | 0.728 | ||||
Female | 23 (16.5) | 41 (23.4) | 18 (17.6) | 21 (20.6) | ||
Male | 116 (83.5) | 134 (76.6) | 84 (82.4) | 81 (79.4) | ||
Smoking, n (%) | 67 (48.2) | 70 (40.0) | 0.146 | 49 (48.0) | 52 (51.0) | 0.736 |
Tumor size, n (%) | 0.117 | 1.000 | ||||
≤ 3 cm | 115 (82.7) | 132 (75.4) | 83 (81.4) | 83 (81.4) | ||
> 3 cm | 24 (17.3) | 43 (24.6) | 19 (18.6) | 19 (18.6) | ||
Tumor number, n (%) | 0.084 | 0.711 | ||||
Solitary | 74 (53.2) | 76 (43.4) | 50 (49.0) | 53 (52.0) | ||
Multiple | 65 (46.8) | 99 (56.6) | 52 (51.0) | 49 (48.0) | ||
Re-TURBT, n (%) | 37 (26.6) | 49 (28.0) | 0.785 | 27 (26.5) | 28 (27.5) | 1.000 |
Pathological stage, n (%) | < 0.001* | 1.000 | ||||
pTa | 94 (67.6) | 67 (38.3) | 57 (55.9) | 58 (56.9) | ||
pT1 | 45 (32.4) | 108 (61.7) | 45 (44.1) | 44 (43.1) | ||
Pathological grade, n (%) | 0.954 | 0.291 | ||||
LG or less | 75 (54.0) | 95 (54.3) | 50 (49.0) | 58 (56.9) | ||
HG | 64 (46.0) | 80 (45.7) | 52 (51.0) | 44 (43.1) | ||
Concomitant carcinoma in situ, n (%) | 11 (7.9) | 18 (10.3) | 0.471 | 11 (10.8) | 9 (8.8) | 0.815 |
Type of intravesical therapy, n (%) | 0.331 | 0.076 | ||||
Early single instillation | 17 (12.2) | 17 (9.7) | 7 (6.9) | 16 (15.7) | ||
Adjuvant chemotherapy or BCG | 25 (18.0) | 23 (13.1) | 19 (18.6) | 14 (13.7) | ||
Combined therapy | 97 (69.8) | 135 (77.1) | 76 (74.5) | 72 (70.6) | ||